Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Asthma-IV: Nursing Management01:30

Asthma-IV: Nursing Management

The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stop antibiotics when you feel better? Opportunities, challenges and research directions.

JAC-antimicrobial resistance·2024
Same author

Lower-limb intramedullary nailing in patients with polyostotic fibrous dysplasia who had a previous unsuccessful treatment. A report of 48 cases.

Journal of orthopaedics and traumatology : official journal of the Italian Society of Orthopaedics and Traumatology·2023
Same author

Pycnogenol® Supplementation Prevents Recurrent Urinary Tract Infections/Inflammation and Interstitial Cystitis.

Evidence-based complementary and alternative medicine : eCAM·2021
Same author

Infection rate of intramedullary nailing for treatment of lower limb polyostotic fibrous dysplasia.

Journal of biological regulators and homeostatic agents·2020
Same author

Structured reporting of chest CT in COVID-19 pneumonia: a consensus proposal.

Insights into imaging·2020
Same author

Prenatal exposure to different diets influences programming of glucose and insulin metabolism in dairy ewes.

Journal of dairy science·2020

Related Experiment Video

Updated: May 27, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Pycnogenol® improvements in asthma management.

G Belcaro1, R Luzzi, P Cesinaro Di Rocco

  • 1Irvine3 Labs, Department of Biomedical Sciences Chieti - Pescara University, Pescara, Italy. cardres@abol.it

Panminerva Medica
|November 24, 2011
PubMed
Summary
This summary is machine-generated.

Pycnogenol® supplementation significantly improved allergic asthma control. Patients taking Pycnogenol® with inhaled corticosteroids (ICS) required less medication and experienced fewer symptoms compared to ICS-only users.

More Related Videos

Acupuncture in a Rat Model of Asthma
07:14

Acupuncture in a Rat Model of Asthma

Published on: August 25, 2020

Related Experiment Videos

Last Updated: May 27, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Acupuncture in a Rat Model of Asthma
07:14

Acupuncture in a Rat Model of Asthma

Published on: August 25, 2020

Area of Science:

  • Respiratory Medicine
  • Pharmacology
  • Natural Product Research

Background:

  • Asthma is a chronic inflammatory respiratory disorder requiring effective management strategies.
  • Pycnogenol®, a pine bark extract, exhibits anti-inflammatory properties by inhibiting leukotriene production.
  • Current asthma therapy often involves inhaled corticosteroids (ICS), with a goal to simplify management and reduce medication reliance.

Purpose of the Study:

  • To evaluate the efficacy of Pycnogenol® as an adjunct therapy for improving allergic asthma control.
  • To assess if Pycnogenol® can support a reduction in the dosage and frequency of inhaled corticosteroid (ICS) administration.
  • To investigate the impact of Pycnogenol® on asthma symptoms, control levels, and specific IgE titers.

Main Methods:

  • A six-month study involving 76 patients with stable allergic asthma (dust mite allergy).
  • Patients received either Pycnogenol® (100 mg/day) plus ICS or ICS alone.
  • Asthma severity was assessed using a five-step therapeutic ranking based on fluticasone propionate dosage.

Main Results:

  • 55% of patients on Pycnogenol® + ICS improved to a lower ICS dose step, versus 6% on ICS alone (P<0.05).
  • No deterioration in asthma control was observed in the Pycnogenol® group, unlike 18.8% in the ICS-only group.
  • Significant improvements were noted in the Pycnogenol® group for reduced night awakenings, fewer days with PEF<80%, less need for rescue medication, and improved symptom scores (cough, wheezing, dyspnea).
  • Specific IgE titers decreased by 15.2% in the Pycnogenol® + ICS group, while increasing by 13.4% in the ICS-only group.

Conclusions:

  • Pycnogenol® supplementation is effective in enhancing the control of allergic asthma signs and symptoms.
  • Adjunctive use of Pycnogenol® with ICS can reduce the overall need for asthma medication.
  • Pycnogenol® demonstrates good tolerability and may allow for reduced ICS dosage in asthma management.